Search

Your search keyword '"Lefeuvre-Plesse, C"' showing total 130 results
Start Over Author "Lefeuvre-Plesse, C"
130 results on '"Lefeuvre-Plesse, C"'

1. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

Author

Ray-Coquard, I., Leary, A., Pignata, S., Cropet, C., González-Martín, A., Marth, C., Nagao, S., Vergote, I., Colombo, N., Mäenpää, J., Selle, F., Sehouli, J., Lorusso, D., Guerra Alia, E.M., Bogner, G., Yoshida, H., Lefeuvre-Plesse, C., Buderath, P., Mosconi, A.M., Lortholary, A., Burges, A., Medioni, J., El-Balat, A., Rodrigues, M., Park-Simon, T.-W., Dubot, C., Denschlag, D., You, B., Pujade-Lauraine, E., and Harter, P.

Published
2023
Full Text
View/download PDF

3. Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network

Author

Derquin, F., Floquet, A., Hardy-Bessard, A.C., Edeline, J., Lotz, J.P., Alexandre, J., Pautier, P., Angeles, M.A., Delanoy, N., Lefeuvre-Plesse, C., Cancel, M., Treilleux, I., Augereau, P., Lavoue, V., Kalbacher, E., Berton Rigaud, D., Selle, F., Nadeau, C., Gantzer, J., Joly, F., Guillemet, C., Pomel, C., Favier, L., Abdeddaim, C., Venat-Bouvet, L., Provansal, M., Fabbro, M., Kaminsky, M.C., Lortholary, A., Lecuru, F., Coquard, I. Ray, and de La Motte Rouge, T.

Published
2020
Full Text
View/download PDF

4. The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study

Author

Lenck, C., Chopin, N., Gouy, S., Bonsang-Kitzis, H., Martinez-Gomez, C., Radosevic-Robin, N., Martin, S., Lefeuvre-plesse, C., Lambaudie, E., Leblanc, E., Guyon, F., Classe, J.-M., Ramanah, R., Beurrier, F., Angeles, M.A., Pomel, C., Joly, F., de la Motte Rouge, T., Provansal, M., Lesoin, A., Floquet, A., Berton, D., Kalbacher, E., Chakiba, C., Meeus, P., Selle, F., Treilleux, I., Lecuru, F., Pautier, P., and Ray-Coquard, I.

Published
2020
Full Text
View/download PDF

6. 193MO Development of a deep learning model using a large real-world database to predict overall survival in patients with metastatic breast cancer (MBC)

Author

Vuduc, L., primary, Jacot, W., additional, Frenel, J-S., additional, Brain, E.G.C., additional, Dieras, V.C., additional, Bachelot, T., additional, Mailliez, A., additional, Dalenc, F., additional, Cottu, P.H., additional, Arnedos, M., additional, Lefeuvre-Plesse, C., additional, Gonçalves, A., additional, Grinda, T., additional, Antoine, A., additional, Chevrot, M., additional, Perol, D., additional, Cournede, P-H., additional, and Delaloge, S., additional

Published
2023
Full Text
View/download PDF

7. HOW THE CONFORMITY OF SURGICAL PRACTICE WITH THE NATIONAL GUIDELINES IMPROVED THE QUALITY OF MANAGEMENT OF OVARIAN GRANULOSA CELL TUMORS (GCT)? A TMRG AND GINECO GROUP STUDY: EP1225

Author

Lenck, C, Chopin, N, Gouy, S, Kitzis, Bonsang H, Gomez, Martinez C, Radosevic-Robin, N, Martin, S, Lefeuvre-Plesse, C, Lambaudies, E, Leblanc, E, Guyon, F, Classe, J-M, Ramanah, R, Beurrier, F, Angeles-Fite, M, Pomel, C, Joly, F, De La Motte Rouge, T, Provansal, M, Lesoin, A, Floquet, A, Berton-Rigaud, D, Kalbacher, E, Meus, P, Selle, F, Treilleux, I, Lecuru, F, Pautier, P, and Ray-Coquard, I

Published
2019
Full Text
View/download PDF

8. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

Author

Ray-Coquard, I, Leary, A, Pignata, S, Cropet, C, González-Martin, A, Marth, C, Nagao, S, Vergote, I, Colombo, N, Mäenpää, J, Selle, F, Sehouli, J, Lorusso, D, Alia, E, Bogner, G, Yoshida, H, Lefeuvre-Plesse, C, Buderath, P, Mosconi, A, Lortholary, A, Burges, A, Medioni, J, El-Balat, A, Rodrigues, M, Park-Simon, T, Dubot, C, Denschlag, D, You, B, Pujade-Lauraine, E, Harter, P, Alia, E M Guerra, Mosconi, A M, Park-Simon, T-W, Ray-Coquard, I, Leary, A, Pignata, S, Cropet, C, González-Martin, A, Marth, C, Nagao, S, Vergote, I, Colombo, N, Mäenpää, J, Selle, F, Sehouli, J, Lorusso, D, Alia, E, Bogner, G, Yoshida, H, Lefeuvre-Plesse, C, Buderath, P, Mosconi, A, Lortholary, A, Burges, A, Medioni, J, El-Balat, A, Rodrigues, M, Park-Simon, T, Dubot, C, Denschlag, D, You, B, Pujade-Lauraine, E, Harter, P, Alia, E M Guerra, Mosconi, A M, and Park-Simon, T-W

Abstract

Background: In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly diagnosed advanced ovarian cancer patients in clinical response after first-line platinum-based chemotherapy plus bevacizumab, irrespective of surgical status. Prespecified, exploratory analyses by molecular biomarker status showed substantial benefit in patients with a BRCA1/BRCA2 mutation (BRCAm) or homologous recombination deficiency (HRD; BRCAm and/or genomic instability). We report the prespecified final overall survival (OS) analysis, including analyses by HRD status. Patients and methods: Patients were randomized 2 : 1 to olaparib (300 mg twice daily; up to 24 months) plus bevacizumab (15 mg/kg every 3 weeks; 15 months total) or placebo plus bevacizumab. Analysis of OS, a key secondary endpoint in hierarchical testing, was planned for ∼60% maturity or 3 years after the primary analysis. Results: After median follow-up of 61.7 and 61.9 months in the olaparib and placebo arms, respectively, median OS was 56.5 versus 51.6 months in the intention-to-treat population [hazard ratio (HR) 0.92, 95% confidence interval (CI) 0.76-1.12; P = 0.4118]. Subsequent poly(ADP-ribose) polymerase inhibitor therapy was received by 105 (19.6%) olaparib patients versus 123 (45.7%) placebo patients. In the HRD-positive population, OS was longer with olaparib plus bevacizumab (HR 0.62, 95% CI 0.45-0.85; 5-year OS rate, 65.5% versus 48.4%); at 5 years, updated PFS also showed a higher proportion of olaparib plus bevacizumab patients without relapse (HR 0.41, 95% CI 0.32-0.54; 5-year PFS rate, 46.1% versus 19.2%). Myelodysplastic syndrome, acute myeloid leukemia, aplastic anemia, and new primary malignancy incidence remained low and balanced between arms. Conclusions: Olaparib plus bevacizumab provided clinically meaningful OS improvement for first-line patients with HRD-positive ovarian cancer. These prespecified expl

Published
2023

9. 176O Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

Author

Nagao, S., primary, Harter, P., additional, Leary, A., additional, Cropet, C., additional, Pignata, S., additional, Fujiwara, K., additional, Gonzalez Martin, A.J., additional, Bogner, G., additional, Vergote, I., additional, Colombo, N., additional, Maenpaa, J., additional, Selle, F., additional, Schmalfeldt, B., additional, Scambia, G., additional, Guerra Alia, E.M., additional, Lefeuvre-Plesse, C., additional, Belau, A., additional, Lortholary, A., additional, Gropp-Meier, M., additional, Pujade-Lauraine, E., additional, and Ray-Coquard, I., additional

Published
2022
Full Text
View/download PDF

11. 144P Development of a 6-color multiplex crystal digital PCR assay for the simultaneous detection of ESR1 and PIK3CA mutations in the plasma of metastatic breast cancer patients

Author

Corné, J., primary, Quillien, V., additional, Godey, F., additional, Le Du, F., additional, Robert, L., additional, Bourien, H., additional, Brunot, A., additional, Crouzet, L., additional, Perrin, C., additional, Lefeuvre-Plesse, C., additional, Dieras, V.C., additional, and De La Motte Rouge, T., additional

Published
2022
Full Text
View/download PDF

12. LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

Author

Ray-Coquard, I.L., primary, Leary, A., additional, Pignata, S., additional, Cropet, C., additional, Martin, A.J. Gonzalez, additional, Bogner, G., additional, Yoshida, H., additional, Vergote, I.B., additional, Colombo, N., additional, Maenpaa, J., additional, Selle, F., additional, Schmalfeldt, B., additional, Scambia, G., additional, Alia, E.M. Guerra, additional, Lefeuvre-Plesse, C., additional, Belau, A., additional, Lortholary, A., additional, Gropp-Meier, M., additional, Pujade-Lauraine, E., additional, and Harter, P., additional

Published
2022
Full Text
View/download PDF

13. LBA12 eMouvoir: Randomised phase III trial evaluating the impact of a personalized and remote physical activity (PA) for breast cancer survivors (BCS). Results on the quality of life (QoL)

Author

Vanlemmens, L., Lefeuvre-Plesse, C., Thery, J., Bogart, E., Aymes, E., Brochard, M-A., Le Gall, F., Belmimoun, M., Rotsaert, L., Mocaer, H., Prevost, J.B., Chocteau, D., Rhliouch, H., Lauridant Philippin, G., Mulliez, T., Najem, A., Hardy-Bessard, A-C., Lartigau, E., Anota, A., and Le Deley, M-C.

Published
2024
Full Text
View/download PDF

15. 1672P Single-dose NEPA versus 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with risk factors receiving moderately emetogenic chemotherapy (MEC)

Author

Zelek, L., primary, Debourdeau, P., additional, Bourgeois, H., additional, Wagner, J.P., additional, Brocard, F., additional, Lefeuvre-Plesse, C., additional, Chauffert, B., additional, Leheurteur, M., additional, Bachet, J-B., additional, Simon, H., additional, Mayeur, D., additional, Jovenin, N., additional, and Scotté, F., additional

Published
2021
Full Text
View/download PDF

16. 1680P Feasibility of home-based supervised physical activity (SPA) for metastatic cancer patients receiving oral targeted therapy: The AFSOS-Unicancer QUALIOR randomized phase II study

Author

Lobbedez, F. Joly, primary, Lefeuvre-Plesse, C., additional, Charton, E., additional, Helissey, C., additional, Priou, F., additional, Stefani, L., additional, Simmet, V., additional, Garnier-Tixidre, C., additional, Meneveau, N., additional, Houede, N., additional, Salas, S., additional, Bourbouloux, E., additional, Descotes, J-M., additional, Anota, A., additional, Nenan, S., additional, and Rieger, I., additional

Published
2021
Full Text
View/download PDF

17. 102P Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases: Characteristics and validation of prognostic models in a large real-life database

Author

Carausu, M., primary, Carton, M., additional, Darlix, A., additional, Pasquier, D., additional, Leheurteur, M., additional, Debled, M., additional, Mouret-Reynier, M-A., additional, Gonçalves, A., additional, Dalenc, F., additional, Verret, B., additional, Campone, M., additional, Ferrero, J-M., additional, Levy, C., additional, Fumet, J-D., additional, Lefeuvre-Plesse, C., additional, Petit, T., additional, Jouannaud, C., additional, Larrouquere, L., additional, Chevrot, M., additional, and Cabel, L., additional

Published
2021
Full Text
View/download PDF

18. 823P Extended follow-up of a real-world cohort of patients (pts) with BRCA mutation (BRCAm) relapsed epithelial ovarian cancer (EOC) receiving olaparib maintenance therapy: The GINECO RETROLA study

Author

de La Motte Rouge, T., primary, Bengrine Lefevre, L., additional, Mouret-Reynier, M-A., additional, Asselain, B., additional, Lucas, B., additional, Gavoille, C., additional, Cornila, C., additional, Spaeth, D., additional, Colomba, E., additional, Patsouris, A., additional, Fabbro, M., additional, Chakiba, C., additional, Toussaint, P., additional, Simon, H., additional, Berton, D., additional, Garbay, D., additional, Garnier Tixidre, C., additional, Coeffic, D., additional, Collard, O., additional, and Lefeuvre-Plesse, C., additional

Published
2020
Full Text
View/download PDF

19. 58P Detection of PIK3CA mutations in plasma ctDNA by Crystal Digital PCR for the selection of alpelisib treatment in routine clinical practice in advanced breast cancer patients

Author

de La Motte Rouge, T., primary, Le Du, F., additional, Corne, J., additional, Godey, F., additional, Bourien, H., additional, Brunot, A., additional, Crouzet, L., additional, Perrin, C., additional, Lefeuvre-Plesse, C., additional, Dieras, V.C., additional, and Quillien, V., additional

Published
2020
Full Text
View/download PDF

21. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

Author

Fujiwara, K., primary, Harter, P., additional, Leary, A., additional, Perol, D., additional, Pignata, S., additional, González-Martín, A., additional, Petru, E., additional, van Nieuwenhuysen, E., additional, Colombo, N., additional, Mäenpää, J., additional, Selle, F., additional, de Gregorio, N., additional, Lorusso, D., additional, Guerra Alia, E.M., additional, Lefeuvre-Plesse, C., additional, Buderath, P., additional, Lortholary, A., additional, Burges, A., additional, Pujade-Lauraine, E., additional, and Ray-Coquard, I.L., additional

Published
2019
Full Text
View/download PDF

22. EP1225 How the conformity of surgical practice with the national guidelines improved the quality of management of ovarian granulosa cell tumors (GCT)? A TMRG and GINECO group study

Author

Lenck, C, primary, Chopin, N, additional, Gouy, S, additional, Bonsang Kitzis, H, additional, Martinez Gomez, C, additional, Radosevic-Robin, N, additional, Martin, S, additional, Lefeuvre-Plesse, C, additional, Lambaudies, E, additional, Leblanc, E, additional, Guyon, F, additional, Classe, J-M, additional, Ramanah, R, additional, Beurrier, F, additional, Angeles-Fite, M, additional, Pomel, C, additional, Joly, F, additional, De La Motte Rouge, T, additional, Provansal, M, additional, Lesoin, A, additional, Floquet, A, additional, Berton-Rigaud, D, additional, Kalbacher, E, additional, Meus, P, additional, Selle, F, additional, Treilleux, I, additional, Lecuru, F, additional, Pautier, P, additional, and Ray-Coquard, I, additional

Published
2019
Full Text
View/download PDF

23. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

Author

Ray-Coquard, I.L., primary, Pautier, P., additional, Pignata, S., additional, Pérol, D., additional, González-Martín, A., additional, Sevelda, P., additional, Fujiwara, K., additional, Vergote, I.B., additional, Colombo, N., additional, Mäenpää, J., additional, Selle, F., additional, Sehouli, J., additional, Lorusso, D., additional, Alia, E M Guerra, additional, Lefeuvre-Plesse, C., additional, Canzler, U., additional, Lortholary, A., additional, Marmé, F., additional, Pujade-Lauraine, E., additional, and Harter, P., additional

Published
2019
Full Text
View/download PDF

24. Abstract P4-16-02: Fertility preservation before neoadjuvant or adjuvant chemotherapy for breast cancer: Final results of PRESAGE trial

Author

Bordes, V, primary, Palpacuer, C, additional, FRICK, C, additional, Leperlier, F, additional, Dezellus, A, additional, De Blay, P, additional, Delay, F, additional, Sauterey, B, additional, Augereau, P, additional, Duros, S, additional, Lefeuvre-Plesse, C, additional, Lavau, S, additional, Durand, LM, additional, Mouret, MA, additional, Gremeau, AS, additional, Campone, M, additional, and Mirallie, S, additional

Published
2019
Full Text
View/download PDF

25. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Author

Ray-Coquard, I, Pautier, P, Pignata, S, Pérol, D, González-Martín, A, Berger, R, Fujiwara, K, Vergote, I, Colombo, N, Mäenpää, J, Selle, F, Sehouli, J, Lorusso, D, Guerra Alía, E, Reinthaller, A, Nagao, S, Lefeuvre-Plesse, C, Canzler, U, Scambia, G, Lortholary, A, Marmé, F, Combe, P, de Gregorio, N, Rodrigues, M, Buderath, P, Dubot, C, Burges, A, You, B, Pujade-Lauraine, E, Harter, P, Ray-Coquard, Isabelle, Pautier, Patricia, Pignata, Sandro, Pérol, David, González-Martín, Antonio, Berger, Regina, Fujiwara, Keiichi, Vergote, Ignace, Colombo, Nicoletta, Mäenpää, Johanna, Selle, Frédéric, Sehouli, Jalid, Lorusso, Domenica, Guerra Alía, Eva M, Reinthaller, Alexander, Nagao, Shoji, Lefeuvre-Plesse, Claudia, Canzler, Ulrich, Scambia, Giovanni, Lortholary, Alain, Marmé, Frederik, Combe, Pierre, de Gregorio, Nikolaus, Rodrigues, Manuel, Buderath, Paul, Dubot, Coraline, Burges, Alexander, You, Benoît, Pujade-Lauraine, Eric, Harter, Philipp, Ray-Coquard, I, Pautier, P, Pignata, S, Pérol, D, González-Martín, A, Berger, R, Fujiwara, K, Vergote, I, Colombo, N, Mäenpää, J, Selle, F, Sehouli, J, Lorusso, D, Guerra Alía, E, Reinthaller, A, Nagao, S, Lefeuvre-Plesse, C, Canzler, U, Scambia, G, Lortholary, A, Marmé, F, Combe, P, de Gregorio, N, Rodrigues, M, Buderath, P, Dubot, C, Burges, A, You, B, Pujade-Lauraine, E, Harter, P, Ray-Coquard, Isabelle, Pautier, Patricia, Pignata, Sandro, Pérol, David, González-Martín, Antonio, Berger, Regina, Fujiwara, Keiichi, Vergote, Ignace, Colombo, Nicoletta, Mäenpää, Johanna, Selle, Frédéric, Sehouli, Jalid, Lorusso, Domenica, Guerra Alía, Eva M, Reinthaller, Alexander, Nagao, Shoji, Lefeuvre-Plesse, Claudia, Canzler, Ulrich, Scambia, Giovanni, Lortholary, Alain, Marmé, Frederik, Combe, Pierre, de Gregorio, Nikolaus, Rodrigues, Manuel, Buderath, Paul, Dubot, Coraline, Burges, Alexander, You, Benoît, Pujade-Lauraine, Eric, and Harter, Philipp

Abstract

BACKGROUND: Olaparib has shown significant clinical benefit as maintenance therapy in women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of combining maintenance olaparib and bevacizumab in patients regardless of BRCA mutation status is unknown. METHODS: We conducted a randomized, double-blind, international phase 3 trial. Eligible patients had newly diagnosed, advanced, high-grade ovarian cancer and were having a response after first-line platinum-taxane chemotherapy plus bevacizumab. Patients were eligible regardless of surgical outcome or BRCA mutation status. Patients were randomly assigned in a 2:1 ratio to receive olaparib tablets (300 mg twice daily) or placebo for up to 24 months; all the patients received bevacizumab at a dose of 15 mg per kilogram of body weight every 3 weeks for up to 15 months in total. The primary end point was the time from randomization until investigator-assessed disease progression or death. RESULTS: Of the 806 patients who underwent randomization, 537 were assigned to receive olaparib and 269 to receive placebo. After a median follow-up of 22.9 months, the median progression-free survival was 22.1 months with olaparib plus bevacizumab and 16.6 months with placebo plus bevacizumab (hazard ratio for disease progression or death, 0.59; 95% confidence interval [CI], 0.49 to 0.72; P<0.001). The hazard ratio (olaparib group vs. placebo group) for disease progression or death was 0.33 (95% CI, 0.25 to 0.45) in patients with tumors positive for homologous-recombination deficiency (HRD), including tumors that had BRCA mutations (median progression-free survival, 37.2 vs. 17.7 months), and 0.43 (95% CI, 0.28 to 0.66) in patients with HRD-positive tumors that did not have BRCA mutations (median progression-free survival, 28.1 vs. 16.6 months). Adverse events were consistent with the established safety profiles of olaparib and bevacizumab. CONCLUSIONS: In patients with advanced ovarian cancer receiving first-li

Published
2019

26. Need for a stratified analysis in stage I malignant ovarian germ cell tumors (MOGCT): Prospective survival analysis of cases collection from the French rare malignant ovarian tumors (TMRO) network & GINECO group

Author

de la Motte Rouge, T., primary, Derquin, F., additional, Floquet, A., additional, Edeline, J., additional, Lotz, J.-P., additional, Alexandre, J., additional, Pautier, P., additional, Ferron, G., additional, Boissier, E., additional, Lefeuvre-Plesse, C., additional, Vegas, H., additional, Patsouris, A., additional, Kalbacher, E., additional, Berton-Rigaud, D., additional, Hardy Bessard, A.-C., additional, Lavoué, V., additional, and Ray-Coquard, I.L., additional

Published
2018
Full Text
View/download PDF

27. Abstract P3-14-03: PRESAGE : Prospective multicenter feasibility study of fertility preservation before neoadjuvant or adjuvant chemotherapy for breast cancer: Preliminary results

Author

Bordes, V, primary, Frick, C, additional, Leperlier, F, additional, Dezellus, A, additional, De Blay, P, additional, Maigne, F, additional, Sauterey, B, additional, Augereau, P, additional, Lefeuvre-Plesse, C, additional, Campone, M, additional, and Mirallie, S, additional

Published
2018
Full Text
View/download PDF

28. Abstract P5-20-03: Impact of prior adjuvant trastuzumab (aT) on clinical characteristics, patterns of recurrence and outcome in 2863 patients with Her2 positive (HER2+) metastatic breast cancer (MBC)- Results from the French ESME UNICANCER program

Author

Saghatchian, M, primary, Carton, M, additional, Piot, I, additional, Pérol, D, additional, Pistilli, B, additional, Brain, E, additional, Ghouadni, A, additional, Ricci, F, additional, Vanlemmens, L, additional, Loeb, A, additional, Levy, C, additional, Goncalves, A, additional, Dalenc, F, additional, Lefeuvre-Plesse, C, additional, Campone, M, additional, Jaffre, A, additional, Gourgou, S, additional, Cailliot, C, additional, Robain, M, additional, and Dieras, V, additional

Published
2018
Full Text
View/download PDF

29. Emotional distress and subjective impact of the disease in young women with breast cancer and their spouses

Author

Duprez, C. (Christelle), Vanlemmens, L. (Laurence), Untas, A. (Aurélie), Antoine, P. (Pascal), Lesur, A. (Anne), Loustalot, C. (Catherine), Guillemet, C. (Cécile), Leclercq, M. (Monelle), Segura, C. (Carine), Carlier, D. (Damien), Lefeuvre-Plesse, C. (Claudia), Simon, H. (Hélène), Frenel, J.S. (Jean Sébastien), Christophe, V. (Veronique), leclercq, M. (mo), Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Laboratoire de Psychopathologie et Processus de Santé (LPPS (URP_4057)), Université de Paris (UP), Centre Alexis Vautrin (CAV), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Centre Eugène Marquis (CRLCC), CRLCC René Gauducheau, Université de Lille, CNRS, CHU Lille, Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab], Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab), Université de Lille-UNICANCER, Université Paris Cité (UPCité), and Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)

Subjects
Adult, Male, Cancer Research, Emotions, Psychological intervention, subjective experience, [SHS.PSY]Humanities and Social Sciences/Psychology, Breast Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, Disease, [SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, 03 medical and health sciences, [SCCO]Cognitive science, Young Adult, 0302 clinical medicine, Breast cancer, breast cancer, Emotional distress, anxiety, couples, depression, interdependence, young women, medicine, Humans, 030212 general & internal medicine, Spouses, Depression (differential diagnoses), business.industry, General Medicine, Middle Aged, medicine.disease, 3. Good health, Distress, Oncology, Spouse, 030220 oncology & carcinogenesis, Anxiety, Female, medicine.symptom, business, Stress, Psychological, Clinical psychology
Abstract

International audience; AIM: Evaluate the influence of emotional distress of young women with breast cancer and their spouses on their daily subjective experience of the disease, through application of the Actor-Partner Interdependence Model. PATIENTS & METHODS: A total of 112 women under 45 years of age were diagnosed with nonmetastatic breast cancer and their spouses answered self-reported measures of anxiety, depression and subjective experience of the disease and its treatment. RESULTS: The patient's emotional distress influenced more the subjective experience of her spouse than the spouse's emotional distress influenced the patient. The spouse's difficulties depended as much on his own distress level as on the patient's distress level. CONCLUSION: These data confirm the importance of implementing couple-focused interventions.

Published
2017
Full Text
View/download PDF

30. Eribulin is safe and efficient in metastatic breast cancer in elderly patients. Results from the REPROLINE multicentric retro-prospective cohort

Author

Martin-Babau, J., primary, Robert, M., additional, Seegers, V., additional, Paillard, M-J., additional, Pivot, X., additional, Gourmelon, C., additional, Uwer, L., additional, Korenbaum, C., additional, Petit, T., additional, Thery, J-C., additional, Som, M., additional, Lefeuvre-Plesse, C., additional, Perret, C., additional, Simon, H., additional, Hardy-Bessard, A-C., additional, Desclos, H., additional, Bourgeois, H., additional, Campone, M., additional, Tredan, O., additional, and Patsouris, A., additional

Published
2017
Full Text
View/download PDF

31. Abstract PD1-08: High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SAFIR02 BREAST (UCBG-0105/1304)

Author

Gonçalves, A, primary, Bachelot, T, additional, Lusque, A, additional, Arnedos, M, additional, Campone, M, additional, Bièche, I, additional, Lacroix, L, additional, Pierron, G, additional, Dalenc, F, additional, Filleron, T, additional, Sablin, M-P, additional, Jimenez, M, additional, Ferrero, J-M, additional, Lefeuvre-Plesse, C, additional, Bonnefoi, H, additional, Attignon, V, additional, Soubeyran, I, additional, Jezequel, P, additional, Commo, F, additional, and André, F, additional

Published
2017
Full Text
View/download PDF

32. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

Author

Schadendorf, D., Amonkar, M. M., Milhem, M., Grotzinger, K., Demidov, L. V., Rutkowski, P., Garbe, C., Dummer, R., Hassel, J. C., Wolter, P., Mohr, P., Trefzer, U., Lefeuvre-Plesse, C., Rutten, A., Steven, N., Ullenhag, G., Sherman, L., Wu, F. S., Patel, K., Casey, M., Robert, C., Schadendorf, D., Amonkar, M. M., Milhem, M., Grotzinger, K., Demidov, L. V., Rutkowski, P., Garbe, C., Dummer, R., Hassel, J. C., Wolter, P., Mohr, P., Trefzer, U., Lefeuvre-Plesse, C., Rutten, A., Steven, N., Ullenhag, G., Sherman, L., Wu, F. S., Patel, K., Casey, M., and Robert, C.

Abstract

We report the first quality-of-life assessment of a MEK inhibitor in metastatic melanoma from a phase III study. Trametinib prolonged progression-free survival and improved overall survival versus chemotherapy in patients with BRAF V600 mutation-positive melanoma. Less functional impairment, smaller declines in health status, and less exacerbation of symptoms were observed with trametinib

Published
2017

33. LBA10 - Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

Author

Fujiwara, K., Harter, P., Leary, A., Perol, D., Pignata, S., González-Martín, A., Petru, E., van Nieuwenhuysen, E., Colombo, N., Mäenpää, J., Selle, F., de Gregorio, N., Lorusso, D., Guerra Alia, E.M., Lefeuvre-Plesse, C., Buderath, P., Lortholary, A., Burges, A., Pujade-Lauraine, E., and Ray-Coquard, I.L.

Published
2019
Full Text
View/download PDF

34. LBA2_PR - Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

Author

Ray-Coquard, I.L., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Sevelda, P., Fujiwara, K., Vergote, I.B., Colombo, N., Mäenpää, J., Selle, F., Sehouli, J., Lorusso, D., Alia, E M Guerra, Lefeuvre-Plesse, C., Canzler, U., Lortholary, A., Marmé, F., Pujade-Lauraine, E., and Harter, P.

Published
2019
Full Text
View/download PDF

35. Concerns of young women with breast cancer and theirs partners from chemotherapy to follow-up: a cross-sectional study

Author

Vanlemmens, L., primary, Congard, A., additional, Duprez, C., additional, Baudry, A.-S., additional, Lesur, A., additional, Loustalot, C., additional, Guillemet, C., additional, Leclercq, M., additional, Levy, C., additional, Carlier, D., additional, Lefeuvre-Plesse, C., additional, Simon, H., additional, Frenel, J.-S., additional, Antoine, P., additional, and Christophe, V., additional

Published
2016
Full Text
View/download PDF

36. 938PD - Need for a stratified analysis in stage I malignant ovarian germ cell tumors (MOGCT): Prospective survival analysis of cases collection from the French rare malignant ovarian tumors (TMRO) network & GINECO group

Author

de la Motte Rouge, T., Derquin, F., Floquet, A., Edeline, J., Lotz, J.-P., Alexandre, J., Pautier, P., Ferron, G., Boissier, E., Lefeuvre-Plesse, C., Vegas, H., Patsouris, A., Kalbacher, E., Berton-Rigaud, D., Hardy Bessard, A.-C., Lavoué, V., and Ray-Coquard, I.L.

Published
2018
Full Text
View/download PDF

37. 1865 Activity and toxicity profile of eribulin mesylate in heavily pretreated metastatic breast cancer: An observational study (EVHALAVEN)

Author

Patsouris, A., primary, Septans, A.L., additional, Paillard, M.J., additional, Pivot, X., additional, Soibinet, P., additional, Jovenin, N., additional, Robert, M., additional, Gourmelon, C., additional, Korembaum, C., additional, Petit, T., additional, Martin-babau, J., additional, Brunot, A., additional, Lefeuvre-plesse, C., additional, Adele, M., additional, Bourgeois, H., additional, Som, M., additional, Uwer, L., additional, Campone, M., additional, Campion, L., additional, and Tredan, O., additional

Published
2015
Full Text
View/download PDF

38. 2705 The French National Network dedicated to Ovarian Malignant Rare Tumors (TMRO): How this organization changed management over the time for rare cancers

Author

Pautier, P., primary, Selle, F., additional, Devouassoux-Shisheboran, M., additional, Treilleux, I., additional, Floquet, A., additional, Croce, S., additional, Ferron, G., additional, Mery-Lamarche, E., additional, Pomel, C., additional, Penault-Llorca, F., additional, Leblanc, E., additional, Lefeuvre-Plesse, C., additional, Henno, S., additional, Joly, F., additional, Nadeau, C., additional, Dubois-Gordeeff, A., additional, Chiannilkulchai, N., additional, Genestie, C., additional, and Vacher-Lavenu, M.C., additional

Published
2015
Full Text
View/download PDF

39. 1320 Eribulin mesylate in metastatic breast cancer, a focus on safety and efficacy in elderly patients. Results from the EVHALAVEN multicentric retrospective cohort

Author

Martin-babau, J., primary, Robert, M., additional, Septans, A.L., additional, Paillard, M.J., additional, Pivot, X., additional, Soibinet, P., additional, Gourmelon, C., additional, Brunot, A., additional, Lefeuvre-plesse, C., additional, Korenbaum, C., additional, Petit, T., additional, Marquis, A., additional, Bourgeois, H., additional, Uwer, L., additional, Som, M., additional, Desclos, H., additional, Campone, M., additional, Campion, L., additional, Tredan, O., additional, and Patsouris, A., additional

Published
2015
Full Text
View/download PDF

41. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

Author

Schadendorf, D, Amonkar, M M, Milhem, M, Grotzinger, K, Demidov, L V, Rutkowski, P, Garbe, C, Dummer, R, Hassel, J C, Wolter, P, Mohr, P, Trefzer, U, Lefeuvre-Plesse, C, Rutten, A, Steven, N, Ullenhag, G, Sherman, L, Wu, F S, Patel, K, Casey, M, Robert, C, Schadendorf, D, Amonkar, M M, Milhem, M, Grotzinger, K, Demidov, L V, Rutkowski, P, Garbe, C, Dummer, R, Hassel, J C, Wolter, P, Mohr, P, Trefzer, U, Lefeuvre-Plesse, C, Rutten, A, Steven, N, Ullenhag, G, Sherman, L, Wu, F S, Patel, K, Casey, M, and Robert, C

Abstract

BACKGROUND: In a randomized phase III study, trametinib prolonged progression-free survival and improved overall survival versus chemotherapy in patients with BRAF V600 mutation-positive melanoma. PATIENTS AND METHODS: Patients' quality of life (QOL) was assessed at baseline and follow-up visits using the European Organisation for Research and Treatment of Cancer Core QOL questionnaire. RESULTS: In the primary efficacy population (BRAF V600E+, no brain metastases) from baseline to weeks 6 and 12, patients' global health status scores worsened by 4-5 points with chemotherapy but improved by 2-3 points with trametinib. Rapid and substantive reductions in QOL functionality (e.g. role functioning, 8-11 points at weeks 6 and 12) and symptom exacerbation (e.g. fatigue, 4-8 points; nausea and vomiting, 5 points, both at weeks 6 and 12) were observed in chemotherapy-treated patients. In contrast, trametinib-treated patients reported small improvements or slight worsening from baseline at week 12, depending on the functional dimension and symptom. The mean symptom-scale scores for chemotherapy-treated patients increased from baseline (symptoms worsened) for seven of eight symptoms at week 6 (except insomnia) and six of eight symptoms at week 12 (except dyspnea and insomnia). In contrast, at weeks 6 and 12, the mean symptom-scale scores for trametinib decreased from baseline (symptoms improved) for pain (11-12 points), insomnia (10-12 points), and appetite loss (1-5 points), whereas those for diarrhea worsened (15-16 points). Mixed-model repeated-measures analyses showed significant (P < 0.05) and/or clinically meaningful improvements (small to moderate) from baseline in favor of trametinib for global health; physical, role, and social functioning; fatigue; pain; insomnia; nausea and vomiting; constipation; dyspnea; and appetite at weeks 6 and/or 12. QOL results for the intent-to-treat population were consistent. CONCLUSIONS: This first QOL assessment for a MEK inhibitor in m

Published
2014

43. Abstract P3-09-07: Construction of two quality of life questionnaires from young breast cancer patients and their partner

Author

Vanlemmens, L, primary, Congard, A, additional, Antoine, P, additional, Fournier, E, additional, Lesur, A, additional, Loustalot, C, additional, Guillemet, C, additional, Leclercq, M, additional, Levy, C, additional, Giraud, C, additional, Lefeuvre-Plesse, C, additional, Frenel, J-S, additional, Simon, H, additional, Leroy, T, additional, Becuwe, C, additional, De Cordoue, S, additional, Ferrero, J-M, additional, Nierges, D, additional, Tiberghien, S, additional, Grosjean, J, additional, Prulhiere, K, additional, Chossiere, L, additional, Duprez, C, additional, and Christophe, V, additional

Published
2013
Full Text
View/download PDF

44. Abstract P2-13-10: Prospective randomized and multicentric evaluation of cognition in menopausal breast cancer patients receiving adjuvant hormonotherapy: a phase III study (Preliminary results)

Author

Vanlemmens, L, primary, Delbeuck, X, additional, Servent, V, additional, Mailliez, A, additional, Vanlemmens, L, additional, Lefeuvre-Plesse, C, additional, Kerbrat, P, additional, Petit, T, additional, Fournier, C, additional, Vendel, Y, additional, Clisant, S, additional, Bonneterre, J, additional, Pasquier, F, additional, and Le, Rhun E, additional

Published
2012
Full Text
View/download PDF

49. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

Author

Schadendorf, D., Amonkar, M. M., Milhem, M., Grotzinger, K., Demidov, L. V., Rutkowski, P., Garbe, C., Dummer, R., Hassel, J. C., Wolter, P., Mohr, P., Trefzer, U., Lefeuvre-Plesse, C., Rutten, A., Steven, N., Ullenhag, G., Sherman, L., Wu, F. S., Patel, K., Casey, M., Robert, C., Schadendorf, D., Amonkar, M. M., Milhem, M., Grotzinger, K., Demidov, L. V., Rutkowski, P., Garbe, C., Dummer, R., Hassel, J. C., Wolter, P., Mohr, P., Trefzer, U., Lefeuvre-Plesse, C., Rutten, A., Steven, N., Ullenhag, G., Sherman, L., Wu, F. S., Patel, K., Casey, M., and Robert, C.

Abstract

We report the first quality-of-life assessment of a MEK inhibitor in metastatic melanoma from a phase III study. Trametinib prolonged progression-free survival and improved overall survival versus chemotherapy in patients with BRAF V600 mutation-positive melanoma. Less functional impairment, smaller declines in health status, and less exacerbation of symptoms were observed with trametinib

50. 578P Tertiary cancer prevention: A national evaluation of the practices and perceptions of hospital-based health care professionals (HHCPs) in charge of the follow-up (FU) care of cancer.

Author

Ben Ahmed, T., Veron, L., Dubois-Delaloge, E., Pudlarz, T., Abdayem, P., Vidican, P., Petureau, A., Schillinger, P., Caron, O., Bensen, A., Boucher, S., Khettab, M., Heudel, P-E., Bernard, E., Lefeuvre-Plesse, C., Fervers, B., Luis, I. Vaz, and Delaloge, S.

Subjects
*MEDICAL personnel, *CANCER prevention, *CANCER treatment
Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results